Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 249 participantsVery low